Several early studies revealed that ingested lignans were deglycosylated and converted to mammalian lignans enterolactone and enterodiol by gut microbiota, absorbed into blood, finally excreted in urine, bile and feces [
9]. Lignans such as pinoresinol, lariciresinol, secoisolariciresinol diglucoside (SDG) and matairesinol which represented four different classes of lignans were converted to enterolignans through reduction, O-deglycosylation, O-demethylation, dehydrogenation and dihydroxylation by intestine bacteria [
10]. However, only 55%, 62% and 72% of pinoresinol diglucoside, matairesinol and SDG were converted to enterolignans, respectively(
11). A study showed that one hour after ingestion of sesame seeds, some lignans are quickly detected in the systemic circulation, such as pinoresinol, matairesinol, lariciresinol, secoisolariciresinol and sesamin, while other studies indicated that the enterolignans generally appeared in circulation 8–10 h after intake of dietary lignans [
9]. Sacco et al. reported that after orally administering rats with trimer-labeled SDG for 7 days, 59.8% of the radioactivity, including the prototype and metabolites, was detected in the colon and cecum, while only 0.1% was detected in the entire skeletal tissue [
12]. In addition, the fate of pure compounds does not invariably mirror the bioavailability of lignan within complex food or herbal medicines matrices. Therefore, the above publications suggest that the enterolignans or metabolites of lignans in the circulation might not be able to totally account for the beneficial actions of lignans on bone.